ACADIA Pharmaceuticals Inc Resubmission of sNDA for Pimavanserin for the Treatment of ADP Call Transcript
Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals conference call. My name is Latif, and I will be your coordinator for today. (Operator Instructions)
I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.
Thank you, Latif. Good afternoon, and thank you for joining us. On today's call, Steve Davis, our Chief Executive Officer, will discuss our plan to resubmit the supplemental NDA for pimavanserin. After which, Dr. Serge Stankovic, our President, will provide further detail on our resubmission strategy. Then, following Steve's closing remarks, we will conduct a question-and-answer session. Mark Schneyer, our Chief Financial Officer; and Brendan Teehan, our Chief Operating Officer and Head of Commercial, will also be available for questions and answers.
I would also like to point out that we're using supplement slides, which are available on the Events and Presentations section of our website.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
